http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2475993-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7c112a251c2ec3fd95773b38bdfbfd2 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-285 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 |
filingDate | 2010-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_736da1a03ddc1861c1fc59a60a960763 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c0a2a28aba6e8d4baf231c3518dc008 |
publicationDate | 2012-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2475993-A2 |
titleOfInvention | Method for diagnosing multiple sclerosis |
abstract | Disclosed is a method for diagnosing and prognosing multiple sclerosis and more particularly to a method for diagnosing and prognosing multiple sclerosis by measuring levels of antibodies. The levels of IgM-type anti-Glc(αl,2)Glc(α) or Glc(αl,3)Glc(α) or Glc(αl,6)Glc(α) antibodies in serum act as diagnostic markers for MS disease and as prognostic biomarkers for the conversion of CIS patients suggestive of MS to clinically definite MS (CDMS) within 24 months. |
priorityDate | 2009-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 240.